Explore Follistatin 344 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Follistatin 344 (FST344) is the naturally occurring 344-amino-acid isoform of human follistatin, a high-affinity myostatin and activin antagonist. It has been advanced as an AAV gene-therapy candidate by Jerry Mendell at Nationwide Children's Hospital in Becker muscular dystrophy and inclusion body myositis trials. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when reconstituting Follistatin 344.
Follistatin 344 (FST344) is the 344-amino-acid naturally occurring isoform of human follistatin, a glycoprotein that binds with very high affinity to myostatin (GDF-8) and to several related TGF-beta superfamily ligands (activin A, activin B, GDF-11), preventing their engagement with their cell-surface receptors. The result is functional myostatin pathway antagonism — the same therapeutic logic underlying ACE-031 / ramatercept (covered on the adjacent page on this site) and bimagrumab, but achieved through a fundamentally different molecular approach.
Follistatin 344 (FST-344) is a follistatin protein isoform studied as a myostatin/activin inhibitor for muscle and reproductive research; most published work uses gene therapy rather than injected protein. It ships as a lyophilized protein, so confirm what format you're actually buying and what the certificate of analysis (COA) shows.
Follistatin binds activin A, activin B, and myostatin (GDF-8) — and to a lesser extent GDF-11 and BMP family ligands — with high affinity, sequestering them in soluble form and preventing them from engaging ActRIIA/IIB. In skeletal muscle, the dominant pharmacology is up-stream myostatin inhibition; in the reproductive axis, the dominant pharmacology is activin A neutralisation and suppression of pituitary FSH release.
No regulatory approvals for any follistatin product. The most-advanced clinical work is the Mendell group's AAV1-FS344 intramuscular gene-therapy programme at Nationwide Children's Hospital in Becker muscular dystrophy and sporadic inclusion-body myositis (sIBM). No synthetic-protein follistatin clinical trial has been published. **Typical dose:** No validated dose for synthetic follistatin in humans; no synthetic-protein clinical trial has been published. Published gene-therapy doses (Mendell et al.
Follistatin 344 has a reported half-life of ~1 hour (circulating), and the dose intervals researchers model most often fall around once daily. Circulating follistatin is cleared quickly, so there is little buildup between doses. The myostatin-blocking effect depends on repeated exposure rather than a steady level. It is catalogued under Muscle Peptides on WPA.
29 Follistatin 344 reconstitution calculations have been logged by the WPA community. The most common dose entered is 100mcg (11 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 1mg (27 sessions). The most common dosing frequency is daily (7x/week) (4 logged protocols).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.